SPECIAL NOTICE
A -- Intent to Announce - RPP3 of MCDC OTA
- Notice Date
- 12/1/2016
- Notice Type
- Special Notice
- NAICS
- 541611
— Administrative Management and General Management Consulting Services
- Contracting Office
- Department of the Army, Army Contracting Command, ACC - NJ (W15QKN), BUILDING 10 PHIPPS RD, PICATINNY ARSENAL, New Jersey, 07806-5000, United States
- ZIP Code
- 07806-5000
- Solicitation Number
- W15QKN17Z081R
- Point of Contact
- Alexandra Trunzo, Phone: 9737244179
- E-Mail Address
-
alexandra.m.trunzo.civ@mail.mil
(alexandra.m.trunzo.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- This is not a Request for Prototype Proposals, but for planning purposes only. A project award will not be awarded from this announcement. The Government intends to announce one Request for Prototype Proposals (RPP3) for execution of a project award(s) in support of Medical Countermeasure Systems Research and Development related to specified project requirements. The purpose of this announcement is to provide members of the Medical CBRN Defense Consortium, and industry in general, advanced notification of Government intent. On 08 April 2016, the Government entered into an Other Transaction Agreement (OTA) with one (1) consortium, the Medical CBRN Defense Consortium (MCDC), in support of Medical Countermeasure Systems related research and development prototype projects. It is the intent of the Government to make project award(s) to member(s) of the MCDC as a result of member project proposals submitted via the Request for Prototype Proposals process. RPP 3 - The Government anticipates two (2) projects for white papers and full proposals to be solicited via W15QKN-16-9-1002 - consisting of the following: 1. Development of an FDA-approved countermeasure that demonstrates non-GLP in vivo activity and potential efficacy consistent with the product's intended use in a suitable animal model target at one of the following: o Bacillus anthracis (Anthrax) o Brucella spp. (Brucellosis) o Burkholderia mallei (Glanders) o Burkholderia pseudomallei (Meliodosis) o Francissila tularensis (Tularemia) o Yersinia pestis (Plague) 2. Development of an FDA-approved antiviral medical countermeasure (MCM) that is efficacious against at least one of the viruses in the following families: o Filoviridae (Zaire ebolavirus, Sudan ebolavirus, Marburg marburgvirus, Tai Forest, and Bundibugyo) o Alphaviridae (Eastern Equine Encephalitis, Western Equine Encephalitis, Venezuelan Equine Encephalitis); Bunyaviridae (Hantan) The Government also anticipates one project for full proposal only (no white papers expected) to be solicited via W15QKN-16-9-1002 - consisting of the following: 1. Development of monoclonal antibodies and related technologies as medical countermeasures against aerosolized Venezuelan Equine Encephalitis virus. In order to obtain more information regarding the above projects, you must be a member of the Medical CBRN Defense Consortium (MCDC), http://ncbdconsortium.org. For more information regarding membership or general questions to the MCDC, contact Michael Stebbins, at 843-760-4094 or NCBD.consortium@scra.org.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/d466b0458c42d56a634c3e1a3fd9beeb)
- Record
- SN04340175-W 20161203/161201234114-d466b0458c42d56a634c3e1a3fd9beeb (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |